Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study

Carolina R C Pieterman*, Simona Grozinsky-Glasberg, Dermot O'Toole, James R Howe, Valentina Ambrosini, Susana H Belli, Mikkel Andreassen, Nehara Begum, Timm Denecke, Antongiulio Faggiano, Massimo Falconi, Jo Grey, Ulrich P Knigge, Teodora Kolarova, Bruno Niederle, Els Nieveen van Dijkum, Stefano Partelli, Andreas Pascher, Guido Rindi, Philippe RuszniewskiStefan Stättner, Timon Vandamme, Juan W Valle, Marie-Pierre Vullierme, Staffan Welin, Aurel Perren, Detlef K Bartsch, Gregory K Kaltsas, Gerlof D Valk

*Corresponding author af dette arbejde

Abstract

Multiple Endocrine Neoplasia type 1 (MEN1) Clinical Practice Guidelines (2012) are predominantly based on expert opinion due to limited available evidence at the time, leaving room for interpretation and variation in practices. Evidence on the natural course of MEN1-related neuroendocrine tumours (NET) and the value of screening programs has increased and new imaging techniques have emerged. The aim of this study is to provide insight in the current practices of screening and surveillance for MEN1-related NETs in ENETS Centers of Excellence (CoEs). A clinical practice questionnaire was distributed among all 65 ENETS CoEs. Response rate was 91% (59/65). In 14% of CoEs <10 patients, in 50% 10-49, in 31% 50-100 and in 3 centres (5%) >100 patients with MEN1 are seen. Practices with regard to screening and surveillance of NETs were markedly heterogeneous. Differences between countries were noted in the use of gut hormones for biochemical screening and the choice for imaging modality for screening/surveillance of pancreatic NETs (PanNETs). Magnetic resonance imaging (MRI) is the preferred modality for screening and surveillance of PanNETs, whereas this is computed tomography (CT) for thoracic NETs. Practices regarding screening for thoracic NETs were more homogeneous among larger volume CoEs, with longer screening intervals. The majority of CoEs tailored the surveillance of small pancreatic and lung NETs to observed growth rate. 68% of CoEs advise patients with clinical MEN1 with negative genetic testing to undergo periodic screening like mutation-positive patients. In conclusion, there is still marked heterogeneity in practice, although there are also common trends. Differences were sometimes associated with volume or country, but often no association was found. This underscores the need for clear and evidence-based practice recommendations.

OriginalsprogEngelsk
TidsskriftJournal of Neuroendocrinology
Sider (fra-til)e13468
ISSN0953-8194
DOI
StatusE-pub ahead of print - 26 nov. 2024

Fingeraftryk

Dyk ned i forskningsemnerne om 'Screening and surveillance practices for Multiple Endocrine Neoplasia type 1-related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence (ENETS CoE)-An ENETS MEN1 task force questionnaire study'. Sammen danner de et unikt fingeraftryk.

Citationsformater